Rejuvenate
Assessing the Effects of Increased Mitochondrial Function on Skeletal Muscle Performance in Older Men; a Pilot Study
Sponsor study identifier
interventional
16
1 country
1
Study Start
November 8, 2016
Actual (reported)Primary Completion
June 26, 2018
Actual (reported)Study Completion
December 15, 2019
Actual (reported)As people grow older skeletal muscle gradually becomes smaller and weaker, causing reduced mobility and quality of life. To understand and reverse this negative process investigators need to find new ways of improving the ability of muscle to perform physical activity. There is some evidence that supplements may improve how the mitochondria work, and investigators want to explore this idea in more detail, by measuring how the muscles work and respond to exercise before and after taking the supplement. This will give us the basic information investigators would need to see if this is a useful idea.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 15, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 24, 2016
Actual (reported)June 7, 2016
Actual (reported)November 8, 2016
Actual (reported)June 26, 2018
Actual (reported)December 15, 2019
Actual (reported)Change in mitochondrial function
Mitochondria will be extracted from muscle samples immediately post-biopsy (biopsies taken baseline, day 7 and day 14) and analysed for content and subsequently for oxidative respiratory function using the Seahorse technique, and maximal rates of Adenosine Triphosphate (ATP) production.
Baseline, day 7, day 14
Chronic changes in habitual muscle protein synthetic rates
Baseline and then daily for 14 days
The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
NIHR Exeter Clinical Research Facility
Exeter, Devon, EX2 5DW, United Kingdom
Timothy Etheridge, PhD
University of Exeter
16 participants (actual enrollment reported by the registry).
First Submitted
May 24, 2016
First Posted
June 7, 2016
Study Start
November 8, 2016
Actual (reported)Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
June 26, 2018
Actual (reported)Study Completion
December 15, 2019
Actual (reported)Last Updated
March 10, 2020
Record last verified: 2018-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: